Role for CROs as study deems cancer trials biggest risk for Pharmas

By Gareth Macdonald

- Last updated on GMT

Related tags Cancer

Role for CROs as study deems cancer trials biggest risk for Pharmas
Late-stage cancer trials are the biggest challenge for pharmaceutical and biotech firms according to data presented at the Biotechnology Industry Organisation's (BIO) CEO and investor conference in Washington DC, US this week.

The data, from a BIO and BioMedTracker study​, showed that cancer trials have only an 11 per cent chance of success, which is the lowest rate for any of the indications examined.

It also showed that such trials have the second lowest success rate at Phase II and the lowest chance at Phase III, which makes them a considerable investment risk for pharmaceutical firms.

Michael Hay, senior biotechnology analyst at Sagient Research Systems.said that: “Oncology drugs have the toughest time making their way through the clinic, despite cancer being the most closely studied area in drug development.

Having an up-to-date and detailed picture of clinical success rates, and ultimately how likely a drug is to be approved, is vital to our clients when making investment and business decisions.​ “

The report does not discuss the role contract research in making cancer trials more successful but given the increasing practice of trial research outsourcing this is clearly something to be considered.

Further support for this idea comes from data from the Association of Clinical Research Organisations (ACRO) which shows that, in 2008, 18 per cent of its members were involved in cancer trials.

Within this the most the most common areas of research were: Non-small cell lung cancer, breast cancer, lung cancer, prostate cancer, and leukemia.

Oncology Trials Outsourcing

Clearly then, the challenge of conducting a cancer trial is as important an issue to a CRO as it is to a pharmaceutical firm, requiring close collaboration and an effective working relations ship will be holding a virtual event “Oncology Trials Outsourcing,” to provide a forum for pharma firms and research providers to meet, learn and discuss all the issues.

“Oncology Trials Outsourcing,” will feature presentations covering all the latest trends and success strategies in cancer trial outsourcing with topics like strategic partnering to patient recruitment being accompanied by case studies Q&A sessions.

Find out how to register, attend and even take part in this free virtual event from the comfort of your office at the following address.

See you at the conference, virtually.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Related suppliers